What is it about?
Development of a robust purification method of the capsular polysaccharide from pneumococcus serotype 23 F, which reaches the degree of purity required for vaccine formulation and achieves a final yield adequate for industrial production.
Featured Image
Photo by CDC on Unsplash
Why is it important?
Capsular polysaccharides from pathogenic bacteria are used as antigen of vaccines. For pneumococcus, there are two types of vaccines: 23-valent pneumococcal polysaccharide vaccine (PPV23) and 10 or 13-valent pneumococcal conjugate vaccines (PCV-10 or PCV-13). All these vaccines include polysaccharide from serotype 23F, so methods to purify this molecule from bacterial cells are extremely important.
Perspectives
The method developed for polysaccharide 23F can be applied with minor modifications to other polysaccharides from Streptococcus pneumoniae and to capsular polysaccharides from other pathogenic bacteria.
Dr. Viviane Maimoni Goncalves
Instituto Butantan
Read the Original
This page is a summary of: Purification of capsular polysaccharide from Streptococcus pneumoniae serotype 23F by a procedure suitable for scale-up, Biotechnology and Applied Biochemistry, June 2003, Wiley,
DOI: 10.1042/ba20020075.
You can read the full text:
Contributors
The following have contributed to this page
